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Inhibitex, Inc: Antibody Anti-Infectives
Inhibitex’s core technology may not w
be initially obvious, but it represents f
a strong potential advance in the i
fight against severe bacterial and p
fungal infection. MSCRAMM pro- P
teins, or Microbial Surface Compo- p
nents Recognizing Adhesive Matrix m
Molecules, are at the heart of Alph- o
aretta, GA-based Inhibitex’s anti- i
infective efforts and are the foun-
dation of two products in clinical
testing. “MSCRAMM technology in-
“volves the characterization and
identification of surface proteins on M
pathogenic organisms that allow S
the adhesion of the organism to
Rhost tissues,” explains Joseph M.
Patti, Ph.D., Vice President of Pre- M
clinical Development and Chief Sci- tentific Officer at Inhibitex. “We gen-
berate antibodies against these
MSCRAMM proteins to prevent or m
interfere with the adhesion process, athe first step in initiation of the
thost infection.”
“Our mission,” says CEO William t
D. Johnston, Ph.D., “is to develop tand commercialize antibody pro-
ducts for severe, life-threatening in- e
fections. The reality is that since the –
early 1980s, the number of new an-
Vtibiotics being approved by the FDA
has followed a steady course i
downward.” He adds that large C
pharmaceutical companies are va-
cating the market for new anti-
infective therapies, instead focus-
ing increasingly on chronic, larger-
Mdollar opportunities, leaving a niche
Oopportunity for biotech companies
Rsuch as Inhibitex to meet those de-
omands.
aInhibitex’s market—at least ini-
Mtially—involves infections usually
tfound in the hospital setting, such
aas severe staphylococcal blood-
pstream infections resulting from
mcatheters and other implanted med-
aical devices. And these infections
yare also becoming more common-
yplace outside the hospital, as with
isports-related injury and infection.
sFrom 1994 through 1998, Dr. Patti,
athen at Texas A&M, cofounded Inhib-
oitex as a virtual company while pur-
suing the MSCRAMM/antibody re-
search. “For the first several years he worked with collaborators in the a
ield who had interesting concepts, a
deas, and intellectual property and M
ulled that into the company,” says i
atti. Inhibitex is now a 75-person p
ublic company. In the last 12 h
onths, the company has raised f
ver $100 million in financing, which c
ncluded an IPO in June 2004. lf
P
tWe believe these a
SCRAMM [Microbial
turface Components
aecognizing Adhesive i
atrix Molecules] pro- m
oeins are viable targets
noth from a passive im- “
unity stance, where we l
ire giving preformed an-
iibodies to prevent infec- d
ion, and as an adjunc- r
aive therapy to treat an
xisting infection.” p
Joseph M. Patti, Ph.D., c
hice President of Preclin-
acal Development and c
hief Scientific Officer s
p
g
p
TSCRAMMs: Targets of
tpportunity
eegardless of the type of bacteria
fr fungus, all infectious organisms
fppear to possess MSCRAMM or
tSCRAMM-like proteins. Although
lhese proteins are characterized as
family, each MSCRAMM is the
roduct of a unique gene. A com- A
on MSCRAMM, conserved among I
ll pathogenic organisms, has not M
et been identified. “However, once w
ou understand how these organ- g
sms attach, you can apply the n
ame developmental strategy for “
ny organism you want to focus P
n,” explains Patti. M
The activities of MSCRAMMs t
ave been studied for many years, nlthough not necessarily under that
cronym. For example, the
SCRAMM Inhibitex targets in both
ts Veronate and Aurexis antibody
roducts, clumping factor A (ClfA),
as been investigated for decades
or its putative role in staphylococ-
al infections. “ClfA allows Staphy-
ococcus aureus to specifically bind
ibrinogen and/or fibrin,” explains
atti. That activity causes the dis-
inctive phenotypic clumping of S.
ureus in plasma.
MSCRAMMs have a role in facili-
ating an organism’s ability to initi-
te an infection. The current think-
ng is that different MSCRAMMs
ay be involved in different types
f infections or that some predomi-
ate over others in vivo. Says Patti,
What we have done at Inhibitex is
ook at all the data with the goal of
dentifying which MSCRAMMs are
mportant for infection, which are
ruggable, and which ones can you
aise antibodies against or use as
vaccine.”
Because most of the MSCRAMM
roteins of interest have been
loned, they can be expressed in
igh quantities in Eschericia coli
nd studied; also, many have been
rystallized, so their three-dimen-
ional structures are known. “These
roteins tend to be fairly immuno-
enic, so making antibodies is
retty straightforward,” says Patti.
he key is to find the right antibody
argeting the MSCRAMM of inter-
st. “We looked at 2,000–3,000 dif-
erent antibodies against ClfA be-
ore we found one that has the
otality of activity that we would
ike,” says Patti.
ntibody Therapies
nhibitex has characterized many
SCRAMMs and is targeting them
ith antibodies via various strate-
ies, including polyclonal and mo-
oclonal antibodies and vaccines.
Our approach is two-fold,” says
atti. “We believe these
SCRAMM proteins are viable
argets both from a passive immu-
ity stance, where we are giving
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258preformed antibodies to prevent in- t
fection, and as an adjunctive ther- J
apy to treat an existing infection.” t
Inhibitex is exploiting both modes c
of antibody biological activity. “The c
MSCRAMM attachment to human
tissue is the initiation of infection,” f
says Johnston. By bringing in an i
antibody that binds to that binding m
site on the MSCRAMM protein, the q
first step in infection is avoided. 6
“That is relevant in prophylaxis but a
it also has relevance in a therapeu- J
tic mode because the infection is e
initially isolated before it goes d
through the equivalence of a meta-
static spread through the body,” he n
says. “You’re going to be able to g
mitigate that spread.” Antibodies p
also activate cellular elements of o
the immune system through a pro- c
cess called opsonization or opso- u
nophagocytosis, in which they help w
clear the bacteria from the patient. r
Inhibitex’s two lead products in- a
dependently target both prevention p
and therapy. Its Veronate product, f
now being tested in a phase III P
study as a means to prevent infec- c
tions in very low birth-weight in- t
fants, includes antibodies selected
against two MSCRAMMs—ClfA, for a
S. aureus, and SdrG, for coagulase- c
negative staph (CoNS), or Staphylo- “
coccus epidermidis. “This phase III d
trial is a 2,000-infant prevention o
study where we are administering a
Veronate to premature babies born s
prior to any transfer of maternal an- m
tibodies and who are very likely to s
develop some sort of infection due p
to their prematurity and the mea- m
sures required to sustain life for
those first several weeks, like cath-
Oeters,” says Patti. Adds Johnston,
““While doctors are appropriately fo-
Mcusing on the immediate problems
tin these infants in the NICU, the
idata that has come out recently
mshows these infections lead to life-
Tlong problems.” Research from in-
lvestigators in the National Institute
cof Child Health and Human Devel-
topment Neonatal Research Net-
fwork published findings in Novem-
“ber 2004 showing that infants who
vhad at least one infection were
r40%–70% more likely to develop
pcerebral palsy than a baby who had
mno infection. Similarly, the odds of
Phaving a low Bayley score, a mea-
fsure of mental development, were
c30%–60% higher for a baby who
had an infection. “That just adds tohe critical need for the drug,” says
ohnston. “It is exciting to think
hese drugs could potentially
hange the course of life for these
hildren.”
Results from the phase II dose-
inding Veronate trial involving 504
nfants found that at a dose of 750
g/kg, Veronate reduced the fre-
uency of S. aureus infections by
3%, fungal infections by 67%, and
ll-cause mortality by 36%. As of
anuary 2005, 700 infants had been
nrolled in the phase III US/Cana-
ian trial.
The company’s humanized mo-
oclonal antibody, Aurexis, tar-
eting ClfA, recently completed a
hase II trial to treat life-threatening
r severe S. aureus infections in
onjunction with antibiotics. “It
sed to be that these infections
ere found only in a hospital envi-
onment, but now we are seeing rel-
tively normal immunocompetent
eople showing up at the ICU with
ever and staph in the blood,” says
atti. “The dramatic increase in the
ommunity-acquired staph infec-
ions is particularly worrisome.”
Aurexis is directed against all S.
ureus infections, not just methi-
ilin-resistant S. aureus (MRSA).
The Aurexis antibody activity is in-
ependent of the antibiotic profile
f the organism,” explains Patti. “In
nimal models, we have demon-
trated it works equally well against
ethicillin-sensitive and -resistant
taph.” Top-line data from the
hase II study should be available
id-Q2.
ther Organisms, Other Targets
We believe the ability to target
SCRAMMs represents a platform
echnology,” says Patti. “Accord-
ngly, we are also looking at other
edically important pathogens.”
his includes enterococci, particu-
arly vancomycin-resistant entero-
occi (VRE), now considered the
hird leading cause of hospital in-
ection behind CoNS and S. aureus.
We are working with Dyax to de-
elop a monoclonal antibody with
eactivity against target MSCRAMM
roteins we have identified across
ultiple enterococcal strains,” says
atti. The company is also targeting
ungal infections, such as those
aused by Candida albicans.
Inhibitex will also be studyingAurexis in an open-label trial among
cystic fibrosis patients heavily colo-
nized with staphylococci. “Staph
often leads to exacerbations of the
condition which result in decreased
lung function and require systemic
IV antibiotics,” says Patti, “so we
are looking at the potential of
Aurexis to see if it has any impact
on that heavy colonization with
staph. If successful in modifying
colonization, we would hope to see
a reduction in exacerbations
caused by the staph infection.” This
trial should begin in the second
quarter of 2005. Inhibitex is also
pursuing a vaccine program against
nosocomial staphylococcal infec-
tions in partnership with Wyeth. Ac-
cording to Johnston, “Wyeth has
had this as a goal for years but had
not found an appropriate technol-
ogy until our collaboration was
formed.”
A New Strategy against
Resistance
“We differ from the pack,” explains
Johnston. “When you look at clin-
ical development, most everyone
else is focused on antibiotics where
they are mostly making structural
modifications to improve dose tim-
ing or dosing format.” He points out
that since the advent of antibiotics
60 years ago, “the bugs are mutat-
ing and outrunning the chemists,”
leading to a reduction in the clinical
efficacy of a significant number of
approved antibiotics as microbes
adapt through evolution. “If you
look at the pressure to mutate, or-
ganisms eventually seem to de-
velop an alternative pathway to
block the cidal activity of antibiotics
or find a path around it,” says John-
ston. Inhibitex seeks to offer an al-
ternative strategy by focusing on
antibodies. “The reason this was
not done in the past is because no-
body had the appropriate targets,”
says Johnston. “Now, we do.”
If proven effective, MSCRAMM
antibodies would be a valuable anti-
infective strategy, particularly in
cases in which resistance patterns
have exhausted other options. “Af-
ter examining clinical isolates from
around the world, we have seen no
evidence that the MSCRAMM
target proteins mutate over time,”
adds Johnston. Although this find-
ing may not always remain the
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259case, and long-term efficacy with
MSCRAMM antibodies is not a
guarantee, these new compounds
may well prove to be a very wel-
come therapeutic strategy for re-
ducing infectivity and virulence
against life-threatening infection.
Chemistry & Biology invites your
comments on this topic. Please
write to the editors at chembiol@
cellpress.com
Alice A. McCarthy is a freelance sci-
ence writer based in Gloucester,
MA (alice@alicemccarthy.com).
